Spolia Therapeutics was founded in 2023 to advance treatments for neurodegeneration by targeting metabolic dysregulation in disease. We’re driven by a clear goal: to bring science-backed, precision-targeted solutions to patients and families who urgently need them.
Team
Steven Robinette, PhD
Founder &
Chief Executive Officer
Essra Ridha, MD
President &
Chief Medical Officer
Haojing Rong, PhD
Chief Development Officer
Mark Tebbe, PhD
Chief Technology Officer
Samantha Zappia, MS, RAC
Vice President, Regulatory Affairs
Robert Plasschaert, PhD
Senior Director, Biology
Jenn Newman, PhD
Senior Director, Toxicology
Monica Markham, JD
Director, Operations
Board
Bruce Booth, DPhil
Atlas Venture, Board Chair
Josh Brumm
Forbion
Clay Thorp
Hatteras
Doug Kerr, MD PhD MBA
Independent
Investors
